This topic contains a solution. Click here to go to the answer

Author Question: One of the following is not an advantage of informal presentation. Which one is it? a. It can be ... (Read 10 times)

Brittanyd9008

  • Hero Member
  • *****
  • Posts: 500
One of the following is not an advantage of informal presentation. Which one is it?
 
  a. It can be used as an accommodation for students who cant read
  b. It is time efficient
  c. It requires less planning than other models
  d. It can be effective with large groups of students

Question 2

One of the following statements about informal presentation is not true. Which one is it?
 
  a. It can be used with large groups of students
  b. It can be used with small groups of students
  c. It can be used with students of varying ages and abilities
  d. It can be used with any type of content analysis



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

connor417

  • Sr. Member
  • ****
  • Posts: 329
Answer to Question 1

ANS: C

Answer to Question 2

ANS: D




Brittanyd9008

  • Member
  • Posts: 500
Reply 2 on: Jun 20, 2018
Excellent


deja

  • Member
  • Posts: 332
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

Vaccines cause herd immunity. If the majority of people in a community have been vaccinated against a disease, an unvaccinated person is less likely to get the disease since others are less likely to become sick from it and spread the disease.

Did you know?

The most common childhood diseases include croup, chickenpox, ear infections, flu, pneumonia, ringworm, respiratory syncytial virus, scabies, head lice, and asthma.

Did you know?

Fungal nail infections account for up to 30% of all skin infections. They affect 5% of the general population—mostly people over the age of 70.

Did you know?

The first monoclonal antibodies were made exclusively from mouse cells. Some are now fully human, which means they are likely to be safer and may be more effective than older monoclonal antibodies.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library